ARYA Sciences Acquisition IV, coming up on the third anniversary of its IPO, said it secured $140,000 from its sponsor to deposit into trust in exchange for another month on its completion deadline, which is now Feb. 2. The SPAC drew an additional $100,000 for working capital from the promissory note with its sponsor.
This is the eight of nine monthly extensions awailable to Arya Sciences IV.
The SPAC in February 2022 mutually agreed to terminate a merger agreement with Amicus Therapeutics, citing market conditions for the pullout.
The SPAC raised $130 million in a February 201 IPO to focus on the healthcare industry in the United States and other developed countries. Read more.
